Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. (BNTC) on October 12, 2022. The report addresses Item 5.02 regarding compensatory arrangements for certain officers approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
On October 12, 2022, the Compensation Committee approved the following changes effective October 1, 2022:
- Discretionary Bonuses (FY ending June 30, 2022):
- Dr. Jerel Banks (Executive Chairman and CEO): $260,000.
- Megan Boston (Executive Director): $127,020 (converted from AUD at a rate of AUD 1.00 to USD 0.73).
- Annual Base Salary Increases:
- Dr. Jerel Banks: Increased to $546,000.
- Megan Boston: Increased to $333,427.50 (converted from AUD at a rate of AUD 1.00 to USD 0.73).
- Future Bonus Targets (FY ending June 30, 2023): No changes were made to the target annual discretionary bonus percentages, which remain at 50% of base salary for Dr. Banks and 40% for Ms. Boston.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items beyond the compensation adjustments noted above.
Key Facts for Investor Verification
- Verify the impact of the increased executive compensation on the company's cash burn rate and liquidity position.
- Confirm the specific Australian Dollar (AUD) to USD conversion rates used for Ms. Boston's compensation versus the rate on the filing date.
- Review the company's most recent 10-K or 10-Q to assess overall financial health in the context of these new salary obligations.